Public Company News

MGC Pharmaceuticals has taken the next step towards launching its potentially breakthrough range of cannabis based skincare products next year after Recent microbiology testing in Slovenia showed “no adverse reactions” to MGC cannabis products that treat psoriasis, acne and seborrhoea ailments. The company says it is on track for a full skin care line roll out in 2017. 

Pilbara Minerals have more than doubled their ore reserves at Pilgangoora in WA, paving the way for the world’s biggest lithium project to get even bigger. A 136% increase in reserves has more than doubled the life of the planned mine to 35 years and prompted studies to double output after mining begins in late 2017.

Sipa Resources have more than doubled the anticipated cap on their share purchase plan to $4.2 million after a flood of applications from bullish shareholders. The rush coincides with the start of a maiden drilling program at the Paterson North project, which is on strike from the ground generating so much good news for Antipa and its JV partner Rio Tinto.

Well-known Perth broker Euroz is predicting a 50% increase in the lithium resource at Neometals’ Mt Marion project near Coolgardie. The prediction, which is based on recent spectacular drill results at the project, would take the Mt Marion resource from 60m tonnes to 90m tonnes, placing it right up there with some of the largest hard rock deposits in the world. 

There seems to be no end in sight to the run on Blackham Resources’ share price that started in September last year at 15c and touched $1.15 today on the back of more, classic Blackham, super high grade drill hits at the Matilda Gold project – the project that just keeps on giving.  Results out today include 6.0m @ 26.4 g/t gold, including 1.8 metres at a whopping 83.3 g/t, and 15.6 metres at 7.51 g/t.

Blackham Resources shares have surged again with news that the first gold pour at the 100,000+ ounce-a-year Matilda gold project in Wiluna W.A is just weeks away. The first gold bar at Matilda will mark the first major milestone in Blackham’s remarkable revival of the largely mothballed project in Wiluna. Shares in Blackham surged 4.5c to $1.02 on the news. 

Legend Mining have wasted no time getting back into the field for a series of moving loop electromagnetic survey’s at their Rockford project in the Fraser Range, home to the giant Nova-Bollinger nickel deposit. They recently completed a round of exploratory drilling at Rockford which the company says has greatly assisted it to better understand the geology at the Fraser Range.

Cashed up Neometals is returning $11.3 million to shareholders even before production begins at Mt Marion in the December quarter. The savvy junior held $74 million in cash at 30 June and is distributing to shareholders some of the rewards of its great deal making. This is the second time in a year that Neometals have announced a dividend before production has even started. 

Medical cannabis company MGC Pharmaceuticals has agreed to sell two African-based exploration permits and related data for $500,000 in cash. The legacy mining assets no longer form part of the company's core business focus as it finalises the transition away from mineral exploration as Erin Resources and into a leading edge medical marijuana company. 

New drill results suggest that Neometal’s world-class Mt Marion Lithium Project near Coolgardie is set for even further growth in its total resource and that's in addition to the recently announced 160% increase. Neometals, who today announced the conclusion of their 147 hole drilling program at Mt Marion currently hold a 13.8% free carried stake in the project.

ATM business Stargroup looks set to give its balance sheet a boost by again revaluing its stake in South Korean ATM manufacturer NeoICP after the ATM manufacturer and Stargroup supplier posted a bumper result for the 2016 financial year. Stargroup holds an 11.28% strategic stake in private Korean company NeoICP and will shortly receive a $60 000 dividend cheque.

ASX listed biotech company PharmAust today announced that a leading veterinary specialist would conduct more canine trials with its promising anti-cancer drug "MP"L. NSW-based dog cancer specialist, Dr Angela Frimberger, will evaluate MPL either as a monotherapy or in conjunction with chemotherapy in dogs that have not responded to standard cancer treatments.